Interactions : אינטראקציות

4.5 Interaction with other medicinal products and other forms of interaction
As with other fibrates, bezafibrate must not be combined with HMG-CoA reductase inhibitors due to the risk of rhabdomyolysis.

The product should not be administered together with perhexiline hydrogenmaleate or MAO- inhibitors.

Patients taking cholestyramine and Bezafibrate400 mg retard film-coated tablets concurrently should wait for at least 2 hours between taking both drugs, since cholestyramine affects the absorption of bezafibrate.

A significant but reversible reduction of kidney function (with a corresponding increase in serum creatinine) following the concurrent use of fibrate-containing drugs has been reported in some patients who had undergone an organ transplant and had been on immunosuppressant treatment. For this reason, kidney function should be carefully monitored in these patients and treatment with Bezafibrate400 mg retard film-coated tablets should be ceased where appropriate in case of significant changes in laboratory findings.

Bezafibrate can potentiate the action of coumarin-type anticoagulants. For this reason, the anticoagulant dose should be reduced by 30 - 50% at the beginning of treatment with bezafibrate and re- adjusted once blood coagulation is under control. Re-adjustment of the anticoagulant dose is also required following cessation of bezafibrate treatment.

Bezafibrate can potentiate the action of oral blood sugar-lowering drugs (e.g. sulphonyl ureas) and insulin.

Bezafibrate influences the effects of phenytoin.